Work

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

Year: 2016

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(16)32607-7

Authors: T.A. Yap, M.G. Krebs, S. Postel-Vinay, Y.J. Bang, A. El-Khoueiry, W. Abida, K. Harrington, R. Sundar, L. Carter, E. Castanon-Alvarez, S.A. Im, A. Berges, M. Khan, C. Stephens, G. Ross, J.C. Soria

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2559890484

FWCI: 1.981

Cites:

Cited by: 48

Related to: 10